475 related articles for article (PubMed ID: 31150511)
1. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
[TBL] [Abstract][Full Text] [Related]
2. Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer.
Sivaganesh V; Peethambaran B
Explor Target Antitumor Ther; 2023; 4(6):1188-1209. PubMed ID: 38213538
[TBL] [Abstract][Full Text] [Related]
3. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma.
Liu Y; Yang H; Chen T; Luo Y; Xu Z; Li Y; Yang J
PLoS One; 2015; 10(5):e0127092. PubMed ID: 25978653
[TBL] [Abstract][Full Text] [Related]
4. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
5. miR‑30a inhibits epithelial‑mesenchymal transition and metastasis in triple‑negative breast cancer by targeting ROR1.
Wang X; Qiu H; Tang R; Song H; Pan H; Feng Z; Chen L
Oncol Rep; 2018 Jun; 39(6):2635-2643. PubMed ID: 29693179
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of receptor tyrosine kinase-like orphan receptor 1 in preeclampsia placenta inhibits human trophoblast cell proliferation, migration, and invasion by PI3K/AKT/mTOR pathway accommodation.
Chen J; Yue C; Xu J; Zhan Y; Zhao H; Li Y; Ye Y
Placenta; 2019 Jul; 82():17-24. PubMed ID: 31174622
[TBL] [Abstract][Full Text] [Related]
7. Regulation of valproic acid induced EMT by AKT/GSK3β/β-catenin signaling pathway in triple negative breast cancer.
Ozman Z; Ozbek Iptec B; Sahin E; Guney Eskiler G; Deveci Ozkan A; Kaleli S
Mol Biol Rep; 2021 Feb; 48(2):1335-1343. PubMed ID: 33515347
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
[TBL] [Abstract][Full Text] [Related]
9. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
[TBL] [Abstract][Full Text] [Related]
10. Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
Jouali F; Marchoudi N; Talbi S; Bilal B; El Khasmi M; Rhaissi H; Fekkak J
BMC Cancer; 2018 Sep; 18(1):900. PubMed ID: 30227836
[TBL] [Abstract][Full Text] [Related]
11. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
13. Expression of ROR1 has prognostic significance in triple negative breast cancer.
Chien HP; Ueng SH; Chen SC; Chang YS; Lin YC; Lo YF; Chang HK; Chuang WY; Huang YT; Cheung YC; Shen SC; Hsueh C
Virchows Arch; 2016 May; 468(5):589-95. PubMed ID: 26874851
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
15. AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation.
Gollavilli PN; Kanugula AK; Koyyada R; Karnewar S; Neeli PK; Kotamraju S
FEBS J; 2015 Oct; 282(20):3971-85. PubMed ID: 26236947
[TBL] [Abstract][Full Text] [Related]
16. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
17. ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K/Akt pathway.
Fernández NB; Lorenzo D; Picco ME; Barbero G; Dergan-Dylon LS; Marks MP; García-Rivello H; Gimenez L; Labovsky V; Grumolato L; Lopez-Bergami P
Mol Carcinog; 2016 Nov; 55(11):1772-1785. PubMed ID: 26509654
[TBL] [Abstract][Full Text] [Related]
18. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
19. LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA.
Tang J; Zhong G; Zhang H; Yu B; Wei F; Luo L; Kang Y; Wu J; Jiang J; Li Y; Wu S; Jia Y; Liang X; Bi A
Cell Death Dis; 2018 Dec; 9(12):1167. PubMed ID: 30518934
[TBL] [Abstract][Full Text] [Related]
20. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]